Kidney Cancer: Scotland

Department of Health written question – answered on 16th December 2014.

Alert me about debates like this

Photo of Rosie Cooper Rosie Cooper Labour, West Lancashire

To ask the Secretary of State for Health, with reference to the approval by the Scottish Medicines Consortium of two second line treatments for renal cell carcinoma, if he will direct the Cancer Drug Fund panel to ensure that patients in England will continue to have access to treatments that are available on the NHS in Scotland for that condition.

Photo of George Freeman George Freeman The Parliamentary Under-Secretary of State for Business, Innovation and Skills, The Parliamentary Under-Secretary of State for Health

We have no plans to do so. Decisions on which drugs are made available through the Cancer Drugs Fund are for NHS England’s Cancer Drugs Fund panel, in accordance with the Standard Operating Procedures for the Fund.

There are two drugs for the second-line treatment of renal cell carcinoma – Afinitor (everolimus) and Inlyta (axitinib) - currently available through the Fund.

Inlyta is also being appraised for this condition by the National Institute for Health and Care Excellence and final draft guidance recommending its use was published on 16 December 2014.

NHS England has assured the Department that no patient whose treatment is currently being funded through the Cancer Drugs Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.